DK0839148T3 - (R)-(Z)-1-azabicyclo[2.2.1]heptan-3-on,O-[3-(3-methoxyphenyl)-2-propynyl]oximmaleat som et farmaceutisk middel - Google Patents

(R)-(Z)-1-azabicyclo[2.2.1]heptan-3-on,O-[3-(3-methoxyphenyl)-2-propynyl]oximmaleat som et farmaceutisk middel

Info

Publication number
DK0839148T3
DK0839148T3 DK96915757T DK96915757T DK0839148T3 DK 0839148 T3 DK0839148 T3 DK 0839148T3 DK 96915757 T DK96915757 T DK 96915757T DK 96915757 T DK96915757 T DK 96915757T DK 0839148 T3 DK0839148 T3 DK 0839148T3
Authority
DK
Denmark
Prior art keywords
heptan
azabicyclo
propynyl
methoxyphenyl
pharmaceutical
Prior art date
Application number
DK96915757T
Other languages
Danish (da)
English (en)
Inventor
Yoshihisa Ando Howard
Douglas Barrett Stephen
Carlos Jaen Juan
Edward Rose Steven
Haile Tecle
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0839148T3 publication Critical patent/DK0839148T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
DK96915757T 1995-06-07 1996-05-13 (R)-(Z)-1-azabicyclo[2.2.1]heptan-3-on,O-[3-(3-methoxyphenyl)-2-propynyl]oximmaleat som et farmaceutisk middel DK0839148T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/474,622 US5534522A (en) 1995-06-07 1995-06-07 (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
PCT/US1996/006814 WO1996040687A1 (en) 1995-06-07 1996-05-13 (r)-(z)-1-azabicyclo[2.2.1]heptan-3-one,o-[3-(3-methoxyphenyl)-2-propynyl]oxime maleate as a pharmaceutical agent

Publications (1)

Publication Number Publication Date
DK0839148T3 true DK0839148T3 (da) 2000-05-22

Family

ID=23884337

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96915757T DK0839148T3 (da) 1995-06-07 1996-05-13 (R)-(Z)-1-azabicyclo[2.2.1]heptan-3-on,O-[3-(3-methoxyphenyl)-2-propynyl]oximmaleat som et farmaceutisk middel

Country Status (25)

Country Link
US (1) US5534522A (el)
EP (1) EP0839148B1 (el)
JP (1) JPH11506723A (el)
KR (1) KR100383031B1 (el)
CN (1) CN1063181C (el)
AT (1) ATE187967T1 (el)
BG (1) BG63571B1 (el)
CA (1) CA2219753A1 (el)
CZ (1) CZ286528B6 (el)
DE (1) DE69605800T2 (el)
DK (1) DK0839148T3 (el)
EA (1) EA000381B1 (el)
EE (1) EE03971B1 (el)
ES (1) ES2142586T3 (el)
GE (1) GEP19991874B (el)
GR (1) GR3032772T3 (el)
HK (1) HK1018055A1 (el)
HU (1) HUP9802499A3 (el)
NO (1) NO308901B1 (el)
NZ (1) NZ307946A (el)
PL (1) PL323796A1 (el)
SK (1) SK282824B6 (el)
UA (1) UA46032C2 (el)
WO (1) WO1996040687A1 (el)
ZA (1) ZA964764B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9601909A (pt) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N,n-dietil-8,8-dipropil-2-azaspiro(4,5)decano-2-propan amina dimaleato
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
MXPA06003661A (es) * 2003-10-02 2006-06-05 Pharmacia & Upjohn Co Llc Sales y polimorfos de un compuesto de indolinona sustituido con pirrol.
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
ES2400772T3 (es) * 2005-06-07 2013-04-12 Ramot At Tel Aviv University Ltd. Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7678363B2 (en) * 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090048462A (ko) 2006-07-17 2009-05-13 라모트 앳 텔-아비브 유니버시티 리미티드 통증완화용 ｇａｂａ 접합체
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2252578B1 (en) 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2509603A1 (en) 2009-12-09 2012-10-17 Biolinerx Ltd. Methods of improving cognitive functions
WO2011104637A2 (en) 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
JP5997931B2 (ja) * 2011-05-25 2016-09-28 石原産業株式会社 農園芸用殺菌剤組成物及び植物病害の防除方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306718A (en) * 1990-03-06 1994-04-26 Warner-Lambert Company Oxime and amine substituted azabicyclo and azocyclo muscarinic agonists and methods of treatment
US5346911A (en) * 1990-03-06 1994-09-13 Warner-Lambert Company Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment

Also Published As

Publication number Publication date
EE03971B1 (et) 2003-02-17
CN1186493A (zh) 1998-07-01
BG63571B1 (bg) 2002-05-31
CZ286528B6 (cs) 2000-05-17
NO975704L (no) 1998-01-30
AU697954B2 (en) 1998-10-22
NO308901B1 (no) 2000-11-13
HK1018055A1 (en) 1999-12-10
ZA964764B (en) 1997-01-08
SK164497A3 (en) 1998-06-03
HUP9802499A2 (hu) 1999-04-28
JPH11506723A (ja) 1999-06-15
ES2142586T3 (es) 2000-04-16
CZ381797A3 (cs) 1998-05-13
UA46032C2 (uk) 2002-05-15
GR3032772T3 (en) 2000-06-30
WO1996040687A1 (en) 1996-12-19
EA199800007A1 (ru) 1998-06-25
KR100383031B1 (ko) 2003-10-17
EE9700316A (et) 1998-06-15
CA2219753A1 (en) 1996-12-19
NZ307946A (en) 2001-03-30
US5534522A (en) 1996-07-09
NO975704D0 (no) 1997-12-05
AU5744996A (en) 1996-12-30
EP0839148B1 (en) 1999-12-22
SK282824B6 (sk) 2002-12-03
DE69605800D1 (de) 2000-01-27
PL323796A1 (en) 1998-04-27
EA000381B1 (ru) 1999-06-24
CN1063181C (zh) 2001-03-14
DE69605800T2 (de) 2000-11-16
ATE187967T1 (de) 2000-01-15
BG102078A (en) 1998-11-30
KR19990022572A (ko) 1999-03-25
HUP9802499A3 (en) 1999-06-28
GEP19991874B (en) 1999-12-06
EP0839148A1 (en) 1998-05-06

Similar Documents

Publication Publication Date Title
DK0839148T3 (da) (R)-(Z)-1-azabicyclo[2.2.1]heptan-3-on,O-[3-(3-methoxyphenyl)-2-propynyl]oximmaleat som et farmaceutisk middel
CA2320224A1 (en) Method for modulating macrophage activation
CA2333004A1 (en) Formoterol polymorphs
BR9810623B1 (pt) processo para a preparação de um sal de tartarato de um dipeptìdeo substituìdo como secretagogo de hormÈnio do crescimento, misturas enantioméricas ou seus enantiÈmeros, sal e composto.
CA2356300A1 (en) 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
AU6166996A (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-((aminoiminomethyl)phenylalkyl)- azaheterocyclylamide compounds
WO2000076550A3 (de) Träger-pharmaka-konjugate
AU652778B2 (en) Treatment composition
AU2102497A (en) Resolution of threo-methylphenidate
CA2155323A1 (en) Novel use as anti-inflammatory agents for bis-heterocyclic compounds and pharmaceutical compositions thereof
CA2300289A1 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
CA2170645A1 (en) Process for the preparation of n-methyl-3-(1-methyl-4-piperidinyl)-14-indole-5-ethanesulphonamide
MX9708337A (es) Maleato (r)-(z)-1-azabiciclo [2.2.1]heptan-3-one,0-[3-(3-metoxifenil)-2-propinil]-oxime como un agente farmaceutico.
CA2360894A1 (en) (1-phenacyl-3-phenyl-3-piperidylethyl) piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
DE69522603D1 (de) Verfahren zur Herstellung 2-Methylspiro(1,3-oxathiolan-5,3')chinuclidin
BR9103481A (pt) Composto,estereoisomero,composicao farmaceutica e processo para preparar um composto
AU2280895A (en) Synthesis n-protected amino acids, especially n-boc-l-propargylglycine by zinc-mediated addition or organic halides to glycine cation equivalent
AU6134896A (en) Resolution of 1-azabicyclo{2.2.2}octan-3-amine, 2-(diphenylmethyl)-n -{{2-methoxy-5-(1-methylethyl)phenyl}methyl}
CA2261706A1 (en) The use of growth factor modulating compounds
CA2267947A1 (en) Preparation of 3-fluoro oxindole derivatives
NZ507199A (en) Crystalline forms of 1S-[1alpha(2S*,3R*), 9ALPHA]-6, 10-dioxo-N(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino] octahydro-6H-piridazino[1,2-A][1,2] diazepin- 1-carboxamide
AU8660891A (en) 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds
AU6838690A (en) Organic amine phosphonic acid complexes
MX9701865A (es) Compuestos de dimetil-(3-aril-but-3-enil)-amino como ingredientes activos farmaceuticos.
AU619969C (en) Substituted 1-azabicyclo compounds